Benzinga24 Ağustos 2026 11:35 TR11 gün önce
Alnylam Pharmaceuticals To Present New Clinical And Real-World Data Across Its Transthyretin-Mediated Amyloidosis And Hypertension Programs At ESC Congress 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced that it will present new clinical and real-world data across its transthyretin-mediated amyloidosis (ATTR) and
Haberin Tamamı Kaynağında
Burada gördüğün özet, haber sağlayıcısından geliyor; metnin devamı yayıncının sitesinde — Benzinga
Haberde Geçen Şirketler
Benzer Haberler
Sodexo : Monthly disclosure on share capital and voting rights August 31, 2026
Yahoo1 saat önce
ANF vs. TPR: Which Stock Is the Better Value Option?
Yahoo1 saat önce
Anthropic's IPO Push Just Got a $15 Billion Backstop
Yahoo1 saat önce
Why Is Circle Internet Group, Inc. (CRCL) Up 63.1% Since Last Earnings Report?
Yahoo1 saat önce
Radian (RDN) Up 1.5% Since Last Earnings Report: Can It Continue?
Yahoo1 saat önce